Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Operating Margin (2020 - 2025)

Barinthus Biotherapeutics' Operating Margin history spans 6 years, with the latest figure at 2332400.0% for Q2 2025.

  • For Q2 2025, Operating Margin changed N/A year-over-year to 2332400.0%; the TTM value through Dec 2025 reached 22257.1%, down 2180303.0%, while the annual FY2024 figure was 454.07%, 1000902.0% up from the prior year.
  • Operating Margin reached 2332400.0% in Q2 2025 per BRNS's latest filing, down from 6518.99% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 2332400.0% in Q2 2025.
  • Average Operating Margin over 5 years is 58844.85%, with a median of 2870.7% recorded in 2021.
  • Peak YoY movement for Operating Margin: soared 166952119bps in 2021, then crashed -166718862bps in 2022.
  • A 5-year view of Operating Margin shows it stood at 1666800.0% in 2021, then crashed by -100bps to 388.62% in 2022, then plummeted by -1929bps to 7885.33% in 2023, then skyrocketed by 99bps to 62.66% in 2024, then tumbled by -3722042bps to 2332400.0% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Operating Margin are 2332400.0% (Q2 2025), 6518.99% (Q1 2025), and 62.66% (Q3 2024).